Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Cross-reactivity

Cross-reactivity

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein.

Journal of pharmaceutical sciences·2024

Same author

Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors.

Clinical pharmacology and therapeutics·2024

Same author

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients.

Advances in therapy·2023

Same author

Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy.

CPT: pharmacometrics & systems pharmacology·2023

Same author

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug.

CPT: pharmacometrics & systems pharmacology·2022

Same author

The functional role of the autolysis loop in the regulation of factor X upon hemostatic response.

Journal of thrombosis and haemostasis : JTH·2021

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Extracellular Vesicle Tissue Factor Activity Assay

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Tissue factor and factor VIIa cross-species compatibility.

Tom Knudsen¹, Ole Hvilsted Olsen, Lars Christian Petersen

¹Haemostasis Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Malov, Denmark.

Frontiers in Bioscience (Landmark Edition)

|May 31, 2011

Summary

Understanding species compatibility of tissue factor (TF) and coagulation factor VII (FVII) is vital for interpreting experiments. Cross-species studies reveal insights into human TF-FVIIa complex structure and function.

More Related Videos

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: Jun 1, 2026

Extracellular Vesicle Tissue Factor Activity Assay

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

Biochemistry and Molecular Biology
Hematology
Pharmacology

Background:

Species compatibility knowledge is essential for interpreting in vivo and in vitro experimental data involving human proteins.
The prothrombin time (PT) assay historically contributed to understanding cross-species tissue factor (TF) and coagulation factor VII (FVII) compatibility.
Advancements in recombinant protein expression and amino acid substitution have expanded cross-species TF-FVIIa research.

Purpose of the Study:

To review and compare findings on human TF-FVIIa complex interactions with those from non-human species.
To highlight how cross-species studies enhance understanding of the human TF-FVIIa complex's structure and function.
To identify challenges and insights gained from studying TF-FVIIa interactions across different species.

Main Methods:

Review of existing literature on TF and FVII from various species (cattle, dog, rabbit, mouse, rat, zebrafish).
Characterization of purified recombinant TF and/or FVIIa from different species.
Analysis of intermolecular interactions and biological effects of TF-FVIIa complex formation.

Main Results:

Purified and characterized TF and/or FVIIa from cattle, dog, rabbit, mouse, rat, and zebrafish.
Cross-species studies provide insights into species-specific TF-FVIIa interactions.
Data from non-human TF-FVIIa systems contribute to understanding the human TF-FVIIa complex.

Conclusions:

Cross-species TF-FVIIa research is crucial for interpreting experimental data and understanding human coagulation.
Studying TF and FVIIa from different species advances general knowledge of the human TF-FVIIa complex.
Careful consideration of species differences is necessary when extrapolating findings across borders.